Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward Kanfer

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
British Journal of Haematology|January 15, 2019
Mesenchymal stromal cells for acute graft-versus-host disease: response at 1 week predicts probability of survivalAntonio Galleu, Dragana Milojkovic, Simona Deplano, et al.
Frontiers in Immunology|February 19, 2021
Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell MalignanciesAgnieszka Tomaszewska, Madan Jagasia, Eric Beohou, et al.
Haematologica|May 14, 2026
Glofitamab and epcoritamab for large B cell lymphoma: a real-world retrospective UK analysis of efficacy, tolerability, and impact of treatment sequencingWendy Osborne, Euan Haynes, William Wilson, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
British Journal of Haematology|January 15, 2019
Mesenchymal stromal cells for acute graft-versus-host disease: response at 1 week predicts probability of survivalAntonio Galleu, Dragana Milojkovic, Simona Deplano, et al.
Frontiers in Immunology|February 19, 2021
Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell MalignanciesAgnieszka Tomaszewska, Madan Jagasia, Eric Beohou, et al.
Haematologica|May 14, 2026
Glofitamab and epcoritamab for large B cell lymphoma: a real-world retrospective UK analysis of efficacy, tolerability, and impact of treatment sequencingWendy Osborne, Euan Haynes, William Wilson, et al.
Pageof 2